

SEQUENCE LISTING

<110> Applied Research Systems ARS holding
 5 <120> THERAPEUTIC USES OF CHEMOKINE VARIANTS
 <130> WO933
 <160> 5
 10 <170> PatentIn version 3.0

 <210> 1
 15 <211> 76
 <212> PRT
 <213> Homo sapiens
 <220>
 <223> Human CCL2
 20 <400> 1

 Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15
 25 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 20 25 30
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 30 35 40 45
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met
 50 55 60
 35 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

 <210> 2
 40 <211> 76
 <212> PRT
 <213> synthetic construct
 <220>
 <223> Human CCL2-P8A
 45 <400> 2

 Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15
 50 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 20 25 30
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 55 35 40 45
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met
 50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

5
 <210> 3
 <211> 76
 <212> PRT
 <213> synthetic construct
 10 <220>
 <223> Human CCL2*
 <400> 3

15 Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15
 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 20 20 25 30
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 35 40 45
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile
 25 50 55 60
 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

30
 <210> 4
 <211> 76
 <212> PRT
 <213> synthetic construct
 35 <220>
 <223> Human CCL2*-P8A
 <400> 4

40 Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr
 1 5 10 15
 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr
 45 20 25 30
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala
 35 40 45
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile
 50 50 55 60
 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr
 65 70 75

55
 <210> 5
 <211> 331,
 <212> PRT

<213> synthetic construct

<220>

<223> Human CCL2-P8A_IgG1 fusion protein

5 <400> 5

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr
1 5 10 15

10 Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Ala Val
20 25 30

Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu
35 40 45

15 Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val
50 55 60

20 Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln
65 70 75 80

Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr
85 90 95

25 Pro Lys Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
100 105 110

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
115 120 125

30 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
130 135 140

35 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
145 150 155 160

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
165 170 175

40 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
180 185 190

Leu His Asn Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
195 200 205

45 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
210 215 220

50 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
225 230 235 240

Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
245 250 255

55 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Gln Gly Gln Pro Glu
260 265 270

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe

275 280 285

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
290 295 300

5

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
305 310 315 320

10 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330